Yesterday it reached .61, which represents a run of 48% in under a week. It did so on record volume, so we’re definitely eager to see where the momentum could carry this play that was already on its way back up.
InspireMD, Inc. NSPR
NSPR has been in real trouble in 2018, losing ground at seemingly every turn and unable to get out of its own way. However, through a combination of a South American breakthrough announcement for two of the companies drugs, and being just plain oversold, we’re seeing a marginal premarket gap-up and will want to observe for a more sustained rebound.
The news was pertaining to NSPR receiving regulatory approval from the goverment of Peru for its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ products. Peru has a population of more than 30 million people. (>>View PR)
ARWR, GLOW, MDGS, MBRX, SEE, WBAI, LIQT, PIXY,
Incoming search terms: